Menopause Symptoms and Treatment Options Explained

✓ This content has been medically reviewed by an obstetrician and gynaecologist
Written & medically reviewed by: Op. Dr. Ayşet Jane Özcan, Obstetrics & Gynaecology Specialist
Istanbul Faculty of Medicine · Medical Park Bahçelievler · TJOD and TSRM member
Last updated: 15 October 2026 · Last medical review: 15 October 2026

Menopause is a single point in time — the day twelve months have passed since your last period — but the symptoms that bring women to the clinic usually begin years before that day and can continue for years after it. Hot flushes, broken sleep, a shorter fuse, vaginal dryness, aching joints, a brain that feels one step behind. These are not a change in who you are, and they are not something you are expected to quietly endure. They are the consequence of a falling and fluctuating oestrogen level, and most of them respond to treatment.

This article sets out what the treatment menu genuinely contains: hormonal, non-hormonal, local and lifestyle. What each option is for, who it tends to suit, what the trade-offs are, and how the decision is actually made in the consulting room. I have described medicines by class rather than by brand, and I have deliberately not attached numbers to how well any of them work, because response varies from woman to woman and the plan is adjusted to the person in front of me. What I hope you take from it is a clearer sense of which questions to ask and what a reasonable plan looks like.

What Menopause Actually Is, and Why the Transition Takes Years

Menopause itself is one day. Everything you feel happens during the long run-up to it, called perimenopause, and in the years afterwards. Most women reach menopause somewhere between 45 and 55, with the average around 51. Perimenopause commonly lasts four to eight years, and it is during this phase — not after it — that symptoms are often at their most unpredictable, because oestrogen is not simply low, it is swinging.

The first change is usually in the cycle itself. Periods may come closer together, then further apart, become heavier or lighter, or skip a month and return. That pattern is expected. What is not expected is bleeding between periods, bleeding after sex, or periods that are suddenly far heavier than your normal. Those deserve assessment rather than being filed under the many possible causes of irregular periods, because thyroid disease, fibroids, polyps and endometrial problems also present this way in the forties.

How it is diagnosed

If you are over 45 with typical symptoms and a changing cycle, menopause is a clinical diagnosis. No blood test is required, and a normal hormone level does not rule it out — in perimenopause the level you measure today may be quite different next week. Hormone testing becomes useful under the age of 45, and particularly under 40, where it is used to look for early menopause or premature ovarian insufficiency. The latter affects roughly one in a hundred women under 40, and it changes the conversation completely: for those women, hormone treatment is replacement of what the body should still be producing, and is usually continued to around the average age of menopause.

When menopause is caused by treatment

Menopause does not always arrive gradually. Removal of both ovaries produces an abrupt version of it overnight, and some chemotherapy regimens, pelvic radiotherapy and medicines given deliberately to switch off ovarian function do something similar. Removal of the uterus alone, with the ovaries left in place, does not cause menopause, although it removes the bleeding pattern that would otherwise signal it, so the transition has to be recognised from symptoms instead. Where ovarian function is lost suddenly, and particularly where it is lost young, symptoms tend to be more intense than in a natural transition because there is no gradual adjustment, and the case for hormone replacement until around the usual age of menopause is correspondingly stronger. That conversation is held together with whichever team is treating the underlying condition.

Contraception still matters

Fertility falls steeply in the forties but does not reach zero the moment periods become irregular. As a general rule, contraception is advised until the age of 55, or for one year after the last period if that happens after 50, and for two years if it happens before 50. Hormone therapy for symptoms is not contraception.

Menopause Treatments: The Realistic Menu

There is no single menopause treatment. There is a menu, and most women end up using more than one item from it. Knowing the whole menu before you walk into the appointment makes the conversation far more productive.

• Systemic hormone therapy — oestrogen taken through the skin or by mouth, with a progestogen if you still have a uterus. The option that works most consistently for hot flushes and night sweats.
• Local vaginal oestrogen — a very low-dose cream, pessary, gel or ring used in the vagina for dryness, discomfort and urinary symptoms. A separate decision from systemic therapy, with a different risk profile.
• Non-hormonal prescription medicines — certain antidepressant-class drugs, gabapentin, oxybutynin, clonidine, and the newer neurokinin receptor antagonists, used specifically for vasomotor symptoms.
• Cognitive behavioural therapy — a structured talking therapy recommended in national guidance for hot flushes, sleep and low mood related to menopause. Not a consolation prize; it targets the distress and the sleep disruption directly.
• Lifestyle and trigger management — activity, weight, alcohol, smoking, room temperature, sleep routine, pelvic floor training.
• Bone-specific treatment — for women whose fracture risk is high, separate from symptom control.
• Treating what is not menopause — thyroid disease, iron deficiency, depression, obstructive sleep apnoea and perimenopause all look alike from the outside, and the first job is to make sure we are treating the right thing.

Doing nothing is also a legitimate choice. If symptoms are mild and not interfering with your life, watchful waiting with good information is reasonable, and you can change your mind at any point. What I would not recommend is enduring symptoms that are wrecking your sleep or your work on the assumption that there is nothing to be done.

Hot Flushes and Night Sweats: What Helps

Hot flushes and night sweats, together called vasomotor symptoms, are the most common reason women seek treatment — around three in four women experience them during the transition, and for a substantial minority they are severe enough to disrupt work and sleep. Systemic oestrogen is the treatment that works most consistently for them. If hormone therapy is not suitable or not wanted, there are genuine alternatives, and they are not placebos.

Why they happen

Falling oestrogen destabilises the temperature-regulating centre of the hypothalamus. The narrow band of core temperature your body tolerates without reacting becomes much narrower, so a tiny rise triggers a full heat-dumping response: flushing, sweating, then chills as the body overshoots. This is also why the newer non-hormonal drugs work — they act on the specific neurons in that pathway rather than on hormone levels at all.

The medical options

Systemic oestrogen, by patch, gel, spray or tablet, addresses the underlying driver and is the option that works most consistently. Where oestrogen is unsuitable or not wanted, several non-hormonal prescription medicines act usefully on this pathway, and they are set out drug by drug in their own section further down.

What you can do yourself

Keep the bedroom cool and the bedding light. Dress in layers you can remove without undressing. Identify your own triggers rather than assuming the standard list applies — for many women alcohol, hot drinks, spicy food and stress are the main ones, and the effect of cutting them is real but modest. Cognitive behavioural therapy reduces how much flushes bother you and how much they disturb your sleep, even when the number of flushes does not change much. Flushes do eventually settle, but it is honest to say that for many women they persist for several years rather than months, and they tend to last longer when they start early in perimenopause.

Practical adjustments worth asking for

A good deal of the daily burden of flushes is situational, and small changes make a disproportionate difference. A desk fan, a seat away from a radiator, a window that opens, clothing in natural fibres and in layers, a spare top kept at work, and the freedom to step out of a long meeting are all reasonable adjustments, and many employers now treat them as such. Sleep is usually the thing worth protecting first: a cool room, cotton bedding, separate covers if your partner prefers the room warmer, and a cold drink within reach so that a night waking does not turn into an hour awake. If exhaustion from night sweats is affecting your ability to work or to drive safely, say so explicitly when you see your doctor. It is not a complaint about comfort; it changes how urgently the problem is treated.

Vaginal Dryness and Urinary Symptoms: The Part Nobody Mentions

This group of symptoms behaves differently from hot flushes in one crucial way: it does not resolve on its own. Flushes fade over time. Vaginal and urinary symptoms, now grouped under the term genitourinary syndrome of menopause, tend to progress slowly if untreated. This is the area women are most reluctant to raise and the area where treatment is most reliably helpful, which is an unfortunate combination.

The tissues of the vulva, vagina, urethra and bladder base are oestrogen-dependent. As oestrogen falls they become thinner, less elastic and less well lubricated, and the vaginal environment becomes less acidic. The result can be dryness, burning, itching, pain during sex, urinary urgency and frequency, discomfort on passing urine, and recurrent urinary tract infections. Thinned, fragile tissue can also bleed a little after sex — but bleeding after sex must be examined rather than assumed to be atrophy, because cervical problems and other causes present in exactly the same way.

Local treatment

Vaginal oestrogen, given as a cream, pessary, tablet or slow-release ring, delivers a very small dose directly to the tissue. Absorption into the bloodstream at standard low doses is minimal, which is why it is considered a different decision from systemic hormone therapy: it does not require a progestogen for endometrial protection, it can be used alongside systemic therapy if vaginal symptoms persist, and because the problem returns when treatment stops, it is generally used long term rather than in short courses. Vaginal preparations of prasterone and the oral medicine ospemifene, which is a selective oestrogen receptor modulator, are further options where available.

Non-hormonal measures

Vaginal moisturisers are used regularly, every few days, to maintain tissue hydration. Lubricants are used at the time of sex for comfort. They do different jobs and using one does not replace the other. Water-based or silicone-based products are preferable to oils with condoms. Avoid soaps, douches and perfumed washes inside the vulva.

Pelvic floor muscle training deserves more attention than it usually gets, particularly where urinary leakage or a sensation of heaviness coexists with dryness — the same tissue changes that cause dryness often accompany pelvic organ prolapse, and a physiotherapist with pelvic floor training can make a considerable difference. One caution: not every new itch, discharge or soreness after menopause is atrophy. Thrush, bacterial vaginosis, skin conditions such as lichen sclerosus, and occasionally vulval cancer present in the same way, so new or persistent symptoms should be examined rather than self-treated indefinitely.

When sex has become something to avoid

Pain changes behaviour, and the behaviour then maintains the pain. Where penetration has been sore for months, the pelvic floor commonly learns to tighten in anticipation, so even once the tissue itself has been treated the muscles go on guarding — a pattern that overlaps with vaginismus and its treatment and that responds to tissue treatment, physiotherapy and graded, unhurried practice together rather than to lubricant alone. Desire is a separate thread again: it is shaped by sleep, mood, how you feel in your own body and the state of the relationship at least as much as by a hormone level, and it is worth untangling those strands rather than treating the whole picture as a hormonal problem.

For women who have had breast cancer, this conversation is held jointly with the oncology team. Non-hormonal measures are tried first, and local oestrogen may still be considered on a case-by-case basis when symptoms are severe and other measures have failed.

Mood, Sleep and Memory: What the Transition Does to the Brain

These symptoms are real, they are common, and they are frequently misattributed — by women themselves and sometimes by clinicians — to stress, ageing or character. Perimenopause is a genuine window of increased vulnerability to depressive symptoms, particularly for women who have previously had severe premenstrual symptoms or postnatal depression.

Mood

What women describe most often is not classical depression but irritability, a thin emotional skin, anxiety that arrives without a subject, and a loss of the usual resilience. Where these symptoms are clearly tied to the menopausal transition and accompanied by flushes and sleep disruption, hormone therapy may help. Where there is a diagnosis of clinical depression, antidepressant treatment is the appropriate first-line approach — hormone therapy is not a substitute for it, and national guidance is clear on that point. Cognitive behavioural therapy has good support for low mood and anxiety in this context.

Sleep

It is worth separating three different problems, because the treatments differ. Sleep broken by night sweats improves when the sweats are treated. Primary insomnia — lying awake without flushes, or waking at four in the morning unable to return to sleep — responds best to cognitive behavioural therapy for insomnia, which outperforms sleeping tablets over any meaningful time horizon. Obstructive sleep apnoea becomes considerably more common after menopause and is widely missed in women, who more often report fatigue and insomnia than loud snoring. Unrefreshing sleep with morning headache or witnessed pauses in breathing should prompt a referral.

Brain fog

Difficulty finding words, losing the thread mid-sentence, and a dip in verbal memory are well described during the menopausal transition, and this is reassuringly not the beginning of dementia. For most women these changes are modest and improve in the years after menopause. Sleep deprivation and anxiety amplify them considerably, so treating the sleep often does more for the fog than anything aimed at the fog itself. Hormone therapy is not recommended as a treatment to protect memory or prevent dementia. Before accepting brain fog as menopausal, I check thyroid function, iron and vitamin B12, since all three cause exactly this picture and all three are easy to correct.

Hormone Therapy: Benefits, Risks and Who It Suits

For most healthy women under 60, or within ten years of their last period, who have troublesome vasomotor symptoms, the balance of benefit and risk from hormone therapy is favourable. That is the current position of the major guideline bodies, and it is a meaningful correction to the fear that followed the early reporting of large trials two decades ago. It is still a balance, not a free pass, and it is weighed individually.

What it consists of

The active component for symptoms is oestrogen. If you have a uterus, a progestogen must be given with it to protect the lining of the womb from overstimulation — this is not optional, and it is the most important safety rule in the whole subject. If you still have periods, the progestogen is usually given cyclically so that a withdrawal bleed occurs; once you are past menopause, a continuous combined regimen that aims for no bleeding is typical. The 52 mg levonorgestrel-releasing intrauterine system — the higher-dose device, since the lower-dose coils are not licensed for this purpose and are not adequate for it — can serve as the progestogen component while also providing contraception, which is often an elegant solution in perimenopause; the practicalities of intrauterine devices, including insertion and side effects, are worth reading before you decide. If you already have one of the smaller-dose devices in place, it does not protect the womb lining against systemic oestrogen, and a separate progestogen is still needed, so check which device you have rather than assuming.

Route matters

Oestrogen delivered through the skin as a patch, gel or spray bypasses the liver, and transdermal oestrogen is not associated with the small increase in venous thrombosis risk that oral oestrogen carries. For that reason the transdermal route is generally preferred where there is migraine, a higher body mass index, gallbladder disease, a history of clot risk, or a problem with absorption. Oral tablets remain a reasonable choice for many women who find them simpler.

The risks, stated plainly

Combined hormone therapy is associated with a small increase in breast cancer risk that is related to how long it is used and which diminishes after stopping; oestrogen-only therapy, used by women who have had a hysterectomy, carries a smaller risk. Oral preparations carry a small increase in the risk of venous thrombosis and of stroke, which transdermal preparations do not appear to share. Gallbladder disease is more common with oral use. Hormone therapy is not prescribed for the purpose of preventing heart disease or dementia. Against these sit the benefits: relief of vasomotor symptoms, improvement in sleep and often mood, treatment of genitourinary symptoms, and preservation of bone density while it is taken.

Who it may not suit

Hormone therapy is generally avoided where there is current or past breast cancer or another oestrogen-dependent cancer, unexplained vaginal bleeding that has not yet been investigated, active or recent venous thrombosis, active liver disease, untreated endometrial hyperplasia, or recent heart attack, stroke or angina. Several things that worry women are not barriers: migraine with aura, where the transdermal route is used; fibroids; endometriosis; well-controlled high blood pressure; and a family history of breast cancer, which is a reason for a careful discussion rather than an automatic refusal.

Testosterone

Where distressing low sexual desire persists after hormone therapy has been optimised, testosterone may be added. It is prescribed at low physiological doses with blood monitoring, is unlicensed for women in many countries, and is generally handled by clinicians familiar with its use.

A practical note on bleeding: some irregular spotting in the first three months of a new regimen is common and usually settles. Bleeding that continues beyond that, or starts after a settled period, needs assessment — typically an ultrasound to measure the thickness of the womb lining, and sometimes a sample of it.

Non-Hormonal Medical Options

These are not weaker versions of hormone therapy. They work through different mechanisms, and they are the right choice for a substantial number of women — those who cannot take oestrogen, those who have decided they would rather not, and those whose dominant symptom is better served by something else.

For hot flushes and night sweats

Several medicines in the SSRI and SNRI classes reduce flush frequency and severity, typically at lower doses than are used for depression, and often with an effect visible within a couple of weeks. One important interaction: women taking tamoxifen after breast cancer should avoid paroxetine and fluoxetine, which interfere with its metabolism, and alternatives within the same classes are used instead. Gabapentin is particularly useful where night sweats dominate, taken in the evening, because its sedating effect works in your favour at that hour. Clonidine is available but less effective and more prone to side effects such as dry mouth and low blood pressure. Oxybutynin has evidence for vasomotor symptoms, though its anticholinergic effects make it a cautious choice in older women. The neurokinin receptor antagonists are the first class designed specifically for this pathway; where they are licensed, they require liver function monitoring before and during treatment.

What these medicines will and will not do

Two expectations are worth setting before you start any of them. The first is that they treat flushes and sweats and little else: they do nothing for vaginal dryness, nothing for bone, and nothing for the other consequences of oestrogen loss, so a woman with several problems at once may still need more than one thing. The second is that choosing between them is partly a question of which side effects you can live with — nausea, a dry mouth, drowsiness, a slightly flattened feeling — rather than of which is theoretically strongest. The usual approach is a trial of a few weeks at a modest dose, then a review. If the first choice does not suit you, moving within the same class or to a different class entirely is routine, and it is not a failure of the plan.

For genitourinary symptoms

The local and non-hormonal measures set out earlier apply here, with one addition worth stating plainly: where recurrent urinary tract infections are the main burden, vaginal oestrogen is often the most useful intervention and is frequently overlooked in favour of repeated antibiotic courses.

For sleep and mood

Beyond the approaches already described, clinical hypnosis has reasonable trial support for vasomotor symptoms and for the sleep disruption that comes with them, and it is worth knowing about, although access to a trained practitioner varies considerably.

Other Symptoms That Get Dismissed: Joints, Skin, Heart and Weight

Flushes, dryness and mood get the attention. A good deal of what women actually notice in the years around menopause sits outside that list, is rarely mentioned in the leaflet, and is often put down to age. These symptoms are genuine, and they are worth naming — partly so that you do not feel you are imagining them, and partly because some of them have other causes that should be ruled out rather than absorbed into the diagnosis.

Aching joints and stiffness

Generalised joint and muscle aching, worst first thing in the morning, with stiff hands and sore heels, is one of the commonest complaints in this age group and is reported more often as oestrogen falls. For many women it improves when other menopausal symptoms are treated, although relief of aching is not by itself the reason hormone therapy is prescribed. What matters clinically is not to assume: joints that are hot, visibly swollen, or symmetrically painful with more than an hour of morning stiffness, and aching that comes with rashes, weight loss or fever, point towards inflammatory arthritis or another rheumatological condition and need proper assessment rather than reassurance.

Palpitations, headaches and dizziness

An awareness of the heart thumping or racing, often alongside a flush or at night, is common and usually benign. It should still be mentioned, because an overactive thyroid, anaemia and genuine rhythm disturbances produce the same sensation, and palpitations that come with chest pain, breathlessness at rest, or fainting need assessment the same day rather than at the next review. Headache patterns frequently change during perimenopause, and women with migraine that has always tracked their cycle often find it worsens while hormone levels are fluctuating, then settles after menopause; a steady transdermal oestrogen level tends to suit this group better than a fluctuating oral one. A new headache that is severe, different in character, or comes with neurological symptoms is a different matter and needs urgent attention.

Dryness elsewhere, skin and hair

Oestrogen receptors are not confined to the pelvis. Dry, gritty eyes, a dry or burning mouth, altered taste, itchy skin, skin that feels thinner and bruises more easily, and the odd sensation of insects crawling on the skin are all described. Scalp hair often becomes finer while a few coarser hairs appear on the chin and upper lip. Rapid or patchy hair loss, by contrast, deserves a check of thyroid function, iron stores and vitamin D rather than being written off as hormonal.

Weight, shape and breast changes

Weight gain in midlife owes more to age, falling activity and muscle loss than to menopause itself; what menopause does most clearly is move fat towards the abdomen, so the shape changes even when the scales do not move much. Hormone therapy is not a weight-loss treatment and should not be presented as one, though it does not cause the weight gain it is often blamed for. Breast tenderness and lumpiness commonly fluctuate through perimenopause and again in the first weeks of hormone therapy. A new discrete lump, a change in the shape or skin of the breast, or nipple discharge is never part of that picture and needs examining promptly.

Lifestyle Measures: What Has Evidence, and What Does Not

Lifestyle advice around menopause has become crowded with products and claims. It is worth being clear about which measures have real support and which are being sold to you.

Measures with genuine evidence

• Regular physical activity — robust benefits for mood, sleep quality, weight, bone and cardiovascular risk. It is not a reliable treatment for hot flushes themselves, and it is more honest to say so, but it improves almost everything around them.
• Resistance and weight-bearing exercise — the single most useful thing you can do for bone in midlife, alongside balance work to reduce falls later.
• Stopping smoking — smokers reach menopause earlier, lose bone faster and carry higher cardiovascular risk.
• Limiting alcohol — a common flush trigger, a contributor to disturbed sleep, and relevant to breast cancer risk.
• Maintaining a healthy weight — a higher body mass index is associated with more troublesome vasomotor symptoms as well as with cardiovascular and endometrial risk.
• Adequate calcium and vitamin D — ideally calcium from the diet, with public health guidance in many countries recommending a daily vitamin D supplement, particularly in autumn and winter.
• Mindfulness, relaxation training and yoga — these consistently reduce how much symptoms bother you and improve sleep, even where flush frequency is unchanged. That is a real benefit, not a lesser one, and the same holds for the structured talking therapies described above.
• Pelvic floor muscle training — for leakage, urgency and sexual comfort.
• Cool sleeping environment and a consistent sleep routine — unglamorous and genuinely effective.

Popular measures without convincing evidence

Black cohosh, red clover, evening primrose oil, dong quai, ginseng and isoflavone supplements have been studied repeatedly with inconsistent results, and they are not regulated to the standard of medicines, so content varies between products. Black cohosh has been linked to rare cases of liver injury. St John's wort interacts with a long list of prescription drugs, including some used in breast cancer and in contraception. Eating soy as food is perfectly fine; taking concentrated isoflavone supplements is a different proposition, particularly after breast cancer.

Compounded so-called bioidentical hormones, mixed individually by a pharmacy and often sold alongside saliva hormone testing, are advised against by the major professional bodies. The doses are not standardised, the preparations are not subject to the same regulatory oversight, and saliva testing is not a valid way to guide treatment. Regulated body-identical hormone preparations — such as oestradiol and micronised progesterone — are available on prescription and are a different thing entirely.

Vaginal laser and radiofrequency devices marketed for rejuvenation have insufficient evidence for menopausal symptoms, and regulators have issued warnings about their promotion for this purpose. Magnet therapy, reflexology and homeopathy have no demonstrated effect on menopausal symptoms beyond placebo.

Bone and Cardiovascular Health: Thinking Ten Years Ahead

Symptoms are what bring women to the clinic, but the long-term consequences of oestrogen loss are what make the menopause consultation one of the most valuable midlife health checks available. Both of these risks are modifiable, and both are easier to address at 50 than at 70.

Bone

Bone turnover accelerates in the years immediately around and after the final period, and the fastest loss occurs in that early window. Most women never know it is happening, because low bone density causes no symptoms until a fracture occurs. Risk is higher with early menopause or premature ovarian insufficiency, low body weight, smoking, heavy alcohol use, long-term steroid treatment, certain inflammatory and malabsorption conditions, a parental hip fracture, and any previous fracture from a minor fall. Where several of these are present, a bone density scan and a formal fracture risk assessment are appropriate rather than optional. Hormone therapy preserves bone while it is being taken, which is relevant for women who are taking it for symptoms anyway. For women whose fracture risk is high but who do not need symptom treatment, bone-specific medicines such as bisphosphonates, denosumab or a selective oestrogen receptor modulator are the usual route; these protect bone but do nothing for flushes, which is exactly why the bone conversation and the symptom conversation are held separately even though both stem from the same hormonal change.

Heart and blood vessels

Cardiovascular disease is the leading cause of death in women, and risk rises after menopause. LDL cholesterol tends to rise, blood pressure often creeps up, body fat redistributes centrally, and insulin sensitivity falls. Menopause before 45, and premature ovarian insufficiency in particular, is associated with higher long-term cardiovascular risk, which is one reason hormone replacement is strongly advised in that group until around the usual age of menopause.

Hormone therapy is not started in order to prevent heart disease. However, the timing of initiation matters to the risk profile: when it is begun in women under 60 or within ten years of menopause, the cardiovascular picture is favourable, whereas starting many years after menopause in an older woman is a different proposition. This is the practical reason not to spend five years putting off a conversation you intend to have eventually.

Whatever you decide about hormones, use this decade to have blood pressure, lipids, blood glucose and weight checked, and to make sure cervical screening and breast screening are up to date according to your national programme.

How the Decision Is Made With Your Doctor

There is no algorithm that produces the right menopause treatment from a list of symptoms. The decision is a negotiation between what is bothering you most, what your history allows, and what you are comfortable with. A good consultation moves through roughly the following ground.

What I will ask

• Which symptoms bother you most, and what specifically they are preventing you from doing. A woman whose main problem is night sweats needs a different plan from one whose main problem is painful sex.
• Where you are in the transition: are periods still occurring, how have they changed, and when was the last one.
• Personal history of breast or gynaecological cancer, blood clots, stroke, heart disease, liver disease, migraine and whether it comes with aura, and any abnormal bleeding.
• Family history, particularly of breast cancer, early menopause, osteoporosis and premature cardiovascular disease.
• Smoking, alcohol, activity, weight, blood pressure, and current medicines and supplements, including herbal ones.
• Whether you still need contraception.
• What you have already tried, and what you would prefer not to take.

What is usually examined or tested

Over 45, no blood test is needed to confirm menopause. Blood pressure and weight are recorded. Under 45, hormone levels are checked. A pelvic or vaginal examination is appropriate where there is bleeding, pain, dryness or urinary symptoms, and an ultrasound or an endometrial sample is arranged where bleeding is abnormal. Screening is brought up to date. If fatigue and low mood dominate, thyroid function and iron studies are sensible before everything is attributed to hormones.

What a good decision looks like

You should leave with the options explained in plain language, including the option of no treatment, a clear idea of what each one would and would not be expected to do, and a date to review. You should not feel pushed in either direction. It is entirely reasonable to agree a trial period, see how you feel, and change course. If you would like to discuss your own situation, you can read more about the women's health services offered at the practice and bring a written list of your symptoms with you — in a subject with this many moving parts, a list beats memory.

When to Review Treatment, and When to Seek Care Sooner

Menopause treatment is not set and forget. The standard pattern is a review about three months after starting or after any change of dose or preparation, and then at least once a year.

What the first three months look like

Breast tenderness, mild nausea, leg cramps, headaches and irregular spotting are common when hormone therapy is started and usually settle as the body adjusts. Knowing this in advance prevents many women from abandoning treatment in week three. If symptoms are not improving at all by around three months, the dose, the route or the preparation is reconsidered rather than the whole idea being abandoned — a woman who does not get on with a tablet may do well with a patch.

At the annual review

We revisit whether the treatment is still doing its job, whether anything in your health has changed, blood pressure and weight, screening status, and whether the balance of benefit and risk still favours continuing. There is no arbitrary maximum duration after which hormone therapy must stop; it is a decision renewed each year. When you do stop, reducing gradually over a few months tends to be more comfortable than stopping abruptly, although symptoms may return either way. Women taking hormone replacement for premature ovarian insufficiency normally continue until around the average age of menopause before this conversation changes.

Come back sooner than planned if

• You bleed at all after twelve months without a period. Postmenopausal bleeding always needs investigation, usually with an ultrasound and often a sample of the womb lining. Most causes turn out to be benign, but this is the symptom that must never be ignored.
• Unscheduled bleeding on hormone therapy continues beyond three to six months, or starts again after a settled period.
• You bleed after sex, or have persistent bleeding between periods during perimenopause.
• You notice a new breast lump, a change in breast shape or skin, or nipple discharge.
• You develop pain, swelling or redness in one calf, sudden breathlessness, or chest pain — possible signs of a clot, requiring urgent assessment.
• You have a sudden severe headache, weakness or numbness on one side, difficulty speaking, or loss of vision.
• You have persistent bloating, feeling full quickly, or ongoing pelvic pain — symptoms that should prompt assessment of the ovaries.
• Your skin or eyes turn yellow, or you develop severe upper abdominal pain.
• Your mood deteriorates markedly, or you have thoughts of harming yourself. This is an emergency and deserves immediate help, not a wait for the next review.

Menopause is a long chapter rather than an event, and the plan that suits you at 48 may not be the one that suits you at 56. The point of regular review is not bureaucracy; it is that your body, your risks and your priorities all keep moving.